Last ¥1,879 JPY
Change Today -5.50 / -0.29%
Volume 2.1M
4568 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 2:00 AM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co ltd (4568) Snapshot

Open
¥1,884
Previous Close
¥1,884
Day High
¥1,903
Day Low
¥1,873
52 Week High
01/10/14 - ¥2,007
52 Week Low
08/8/13 - ¥1,581
Market Cap
1.3T
Average Volume 10 Days
1.7M
EPS TTM
¥133.57
Shares Outstanding
709.0M
EX-Date
09/26/14
P/E TM
14.1x
Dividend
¥60.00
Dividend Yield
3.19%
Current Stock Chart for DAIICHI SANKYO CO LTD (4568)

Related News

No related news articles were found.

daiichi sankyo co ltd (4568) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (4568) Details

Daiichi Sankyo Company, Limited is engaged in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Memary and Donepezil for the treatment of alzheimer’s disease; Nexium for treating reflux esophagitis, etc.; Inavir, an anti-influenza treatment product; ActHIB, a haemophilus b conjugate vaccine; and Loxonin S, an analgesic and anti-inflammatory drug. The company’s products also include Denosumab, an antibody for the treatment and prevention of various bone disorders; and Edoxaban, an oral anticoagulant product. In addition, it markets therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome, and metastatic melanoma. Further, the company develops, manufactures, and sells non-prescription medications, non-medical goods, cosmetics, and food products; medical devices for healthcare professionals, clinics, and hospitals; drinking water; and pharmaceuticals and drugs for animals, as well as researches, develops, manufactures, and sells vaccines. Additionally, it is involved in the manufacture and contract manufacture of as active pharmaceutical ingredients and intermediates, as well as in the provision of insurance and real estate agency services. The company has a strategic collaboration with Coherus BioSciences, Inc. for the development and commercialization of biosimilar candidates; strategic alliance with Sanford-Burnham Medical Research Institute to study novel drug targets in cardiovascular-metabolic diseases; and clinical collaboration agreement with Portola Pharmaceuticals, Inc. for Phase III studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

32,791 Employees
Last Reported Date: 06/23/14
Founded in 1899

daiichi sankyo co ltd (4568) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

daiichi sankyo co ltd (4568) Key Developments

Daiichi Sankyo Company, Limited Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2014; Provides Dividend Guidance for the Year Ending March 31, 2015; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2015

Daiichi Sankyo Company, Limited announced consolidated earnings results for the first quarter ended June 30, 2014. For the quarter, the company reported revenue of JPY 254,449 million against JPY 252,637 million a year ago. Operating profit was JPY 29,430 million against JPY 15,180 million a year ago. Profit before tax was JPY 27,925 million against JPY 17,514 million a year ago. Profit attributable to owners of the company was JPY 19,986 million or JPY 28.34 per diluted share against JPY 15,024 million or JPY 21.31 per diluted share a year ago. Revenue at the Group as a whole increased owing to sales growth and beneficial exchange rates in Europe and other regions. Operating profit increased by ¥14.2 billion, or 93.9% year on year. This substantial operating profit increase reflected not only an increase in gross profit but also decreases in selling, general and administrative expenses and research and development expenses. In the first three months of the previous fiscal year, loss on business restructuring at Daiichi Sankyo Europe GmbH was recorded under selling, general and administrative expenses. Profit before tax increased by ¥10.4 billion, or 59.4% year on year. This increase was not as substantial as the operating profit increase owing to a decrease in financial income and an increase in financial expenses. Profit attributable to owners of the company increased by ¥5.0 billion or 33.0% year on year. This increase was not as substantial as profit before tax increase due to an increase in the amount of income taxes. For the year ending March 31, 2015, the company expects to pay a second quarter dividend of JPY 30.00 per share and a year end dividend of JPY 30.00 per share. For the year ending March 31, 2015, on consolidated basis, the company expects revenue of JPY 920,000 million, operating profit of JPY 120,000 million, profit before tax of JPY 120,000 million and profit attributable to owners of the company of JPY 78,000 million or JPY 110.80 per share.

Daiichi Sankyo Company, Limited, Q1 2015 Earnings Call, Jul 31, 2014

Daiichi Sankyo Company, Limited, Q1 2015 Earnings Call, Jul 31, 2014

Portola Pharmaceuticals Enters into Clinical Collaboration Agreement with Daiichi Sankyo for Phase 3 Studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban

Portola Pharmaceuticals announced that it has entered into a second clinical collaboration agreement with Daiichi Sankyo to study andexanet alfa, Portola's investigational Factor Xa inhibitor antidote, in Phase 3 registration studies with Daiichi Sankyo's Factor Xa inhibitor edoxaban. Portola's original collaboration agreement with Daiichi Sankyo, announced in June 2013, covered the conduct of a Phase 2 proof-of-concept study, for which results are anticipated later this year. The Phase 3 edoxaban studies, known as ANNEXA(TM) - E (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors - Edoxaban), are expected to start in 2015. Under this non-exclusive collaboration agreement, Portola will receive an upfront payment and is eligible to receive additional development and regulatory milestone payments. Portola retains full, worldwide commercial rights to andexanet alfa, for which Portola is pursuing an Accelerated Approval pathway.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4568:JP ¥1,878.50 JPY -5.50

4568 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioCryst Pharmaceuticals Inc $12.05 USD -0.47
BioMerieux €77.66 EUR -0.05
Exelixis Inc $3.99 USD -0.045
Ipsen SA €32.85 EUR -0.345
Vertex Pharmaceuticals Inc $86.95 USD -1.96
View Industry Companies
 

Industry Analysis

4568

Industry Average

Valuation 4568 Industry Range
Price/Earnings 21.9x
Price/Sales 1.2x
Price/Book 1.4x
Price/Cash Flow 22.0x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO LTD, please visit www.daiichisankyo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.